Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Q1 2020 Y-mAbs Therapeutics, Inc Earnings Call Transcript

May 08, 2020 / 01:00PM GMT
Release Date Price: $39.84 (+12.51%)
Operator

Welcome to the Y-mAbs First Quarter 2020 Earnings Conference Call. The conference is being recorded.

(Operator Instructions) I would now like to turn the conference over to Thomas Gad, the Chairman and President.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President & Head of Business Development and Strategy

Thank you, and thank you, everyone, for joining this call this morning. I assume most of us are still virtual, hopefully not for long. So despite of the extraordinary circumstances that we have been through in this first quarter, Y-mAbs actually had a great quarter of 2020. We believe we've made significant progress on executing our strategy and taking additional steps that will position us very well for our potential product launch of both naxitamab and omburtamab. We completed the submission of naxitamab BLA to the FDA in March as you know, and expect to complete the rolling BLA submission for omburtamab next month. We are also working very hard on our GD2-GD3 vaccine, which should also expand from a single-center trial into a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot